Dr Reddy's launches antibiotic drug in US market

Tags: Companies
Dr Reddy's Laboratories Ltd has launched Moxifloxacin Hydrochloride tablets in the US market for the treatment of a wide range of diseases, including pneumonia, bronchitis and skin infections.

The drug was launched yesterday following the approval by the United States Food & Drug Administration (USFDA), DRL said in a press release today.

The tablets, a generic version of Avelox 400 mg, are available in bottle counts of 30, it said.

Bayer's Avelox is indicated for the treatment of community acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS), uncomplicated and complicated skin and skin structure infections (uSSSI and cSSSI), mild to moderate pelvic inflammatory disease (PID), and complicated intra-abdominal infections (cIAI), according to Avelox official website.

According to IMS Health, Avelox (moxifloxacin HCl) tablets had a sales figure of approximately $195 millions in 2013, the release said.

Shares of DRL were trading at Rs 2,800 apiece on the BSE during afternoon trade.

EDITORIAL OF THE DAY

  • The government must no longer handhold state-owned banks

    Every year, successive finance ministers are compelled to top up capital levels in state-owned banks.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

BK Chaturvedi

Time to get our energies together

Energy needs of the economy are growing rapidly with rising ...

Kuruvilla Pandikattu SJ

Science & religion go hand in hand

A PJ Abdul Kalam (1931 –2015), the 11th president of ...

Dharmendra Khandal

Go spot a gecko

Iam sure you must have read about how a lizard ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture